Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807053 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)
A Phase 2 study of Rhinitis, Allergic, Seasonal, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT00807053: Completed Phase 2 study of Rhinitis, Allergic, Seasonal, sponsored by AstraZeneca.
NCT00807053 is a Phase 2 study of Rhinitis, Allergic, Seasonal that has completed, run by AstraZeneca. The registered enrollment target is 480 participants, below the 699-participant average among 3 other Rhinitis, Allergic, Seasonal trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00807053, a Phase 2 study of Rhinitis, Allergic, Seasonal, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate the efficacy of ciclesonide HFA, applied as a nasal aerosol once daily, in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ciclesonide HFA
Study Locations (20)
California
- Altana/Nycomed - Mission Viejo
- Altana/Nycomed - Orange
- Altana/Nycomed - San Diego
Georgia
- Altana/Nycomed - Gainsville
- Altana/Nycomed - Savannah
- Altana/Nycomed - Stockbridge
Colorado
- Altana/Nycomed - Colorado Springs
- Altana/Nycomed - Denver
Nebraska
- Altana/Nycomed - Lincoln
- Altana/Nycomed - Papillion
New Jersey
- Altana/Nycomed - Skillman
- Altana/Nycomed - West Brick
Oregon
- Altana/Nycomed - Ashland
- Altana/Nycomed - Medford
Indiana
- Altana/Nycomed - Indianapolis
Kansas
- Altana/Nycomed - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
What the finished NCT00807053 record still lists
NCT00807053 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, below the 699-participant average among 3 other Rhinitis, Allergic, Seasonal trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Rhinitis, Allergic, Seasonal appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00807053 names 20 study sites across 12 states, led by California, Georgia, Colorado.
Frequently Asked Questions
What is clinical trial NCT00807053 about?
NCT00807053 is a clinical study titled "Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)". The primary objective of this study is to demonstrate the efficacy of ciclesonide HFA, applied as a nasal aerosol once daily, in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.
What is the current status of trial NCT00807053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2007-04. Estimated completion is 2007-07.
What conditions does trial NCT00807053 study?
This clinical trial studies the following conditions: Rhinitis, Allergic, Seasonal.
What interventions are being tested in trial NCT00807053?
The interventions under investigation include: Placebo (DRUG), Ciclesonide HFA (DRUG).
Who is sponsoring clinical trial NCT00807053?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00807053 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhinitis, Allergic, Seasonal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine
COMPLETED · Phase 4
-
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)
COMPLETED · Phase 3
-
A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia